Skip to main content

BLEED TREATMENT WHEN THEY NEED IT

BLEED TREATMENT WHEN THEY NEED IT

Prepare your adult and adolescent hemophilia A patients for the unexpected with effective control of bleeding episodes.

BLEED CONTROL THEY CAN COUNT ON

In a Phase 3 pivotal trial, Esperoct® was shown to be effective in controlling 97% of bleeds with 1-2 infusions.1,a

Esperoct® bleed control rate
Esperoct® bleed control rate

PREPARE THEM FOR THE UNEXPECTED

aIn a phase 3, open-label study, safety, pharmacokinetics, and efficacy of Esperoct® were evaluated in PTPs aged >12 years with severe hemophilia A; 175 received routine prophylaxis (50 IU/kg every 4 days) and 12 adults elected to be treated on demand during the main phase. Treatment-requiring bleeds were reported by patients through diaries. 12 patients treated on demand reported 532 of 968 bleeds in the main phase.1

DOSING THAT KEEPS THINGS SIMPLE

Esperoct® dosing for minor bleeds
Esperoct® dosing for minor bleeds
Esperoct® dosing for major bleeds
Esperoct® dosing for major bleeds

bAdditional dose can be administered every 24 hours for major or life-threatening bleeding.

Esperoct® was shown to provide effective perioperative bleed control.

Trial prescription program.

Esperoct® vial

Qualifying patients can receive a trial prescription for Esperoct®. To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information

References:

  1. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
  2. Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.